No Data
No Data
Praxis Precision Medicines to Present on Late-Stage Programs Across Epilepsy and Movement Disorders at the American Academy of Neurology 2025 Annual Meeting
Press Release: Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Praxis Precision Medicines to Participate in Five Upcoming Investor Conferences
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $65 to $120
Analysts Cut Price Targets For Praxis Precision After Trial Setback For Essential Tremor Candidate